What is the current stock price of Cryoport, Inc. (CYRX)?

As of the latest market data, Cryoport, Inc. (CYRX) is trading at $9.67. The stock has seen a loss of -0.92% today.

Does Cryoport, Inc. (CYRX) pay a dividend?

Based on current data, Cryoport, Inc. does not have a confirmed active dividend policy.

What is the market cap of Cryoport, Inc.?

The current market capitalization of Cryoport, Inc. (CYRX) is approximately unavailable.

CYRX

Cryoport, Inc.·Industrials

9.67

0.922%(−0.09)

Market Closed

10.00

3.413%(+0.33)

After Hours

Last Updated: — ET

52W L: $5.2152W H: $11.45

CYRX NEWS

seekingalpha.com

Mar 30

Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven

Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.

defenseworld.net

Mar 23

CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

CryoPort, Inc. (NASDAQ: CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the

seekingalpha.com

Mar 3

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

zacks.com

Mar 3

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.

prnewswire.com

Mar 3

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

prnewswire.com

Feb 17

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close.

Company Profile

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

Sector

Industrials

Industry

Integrated Freight & Logistics

Employees

1,090

IPO Date

2005-08-22

Beta

1.69

Websitewww.cryoport.com↗